Stock Financial Ratios

TXMD / TherapeuticsMD, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,287.14
Enterprise Value ($M)1,075.90
Book Value ($M)127.49
Book Value / Share0.65
Price / Book8.58
NCAV ($M)-4.04
NCAV / Share-0.02
Price / NCAV150.79
Income Statement (mra) ($M)
Net Income-89.88
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio0.45
Current Ratio0.53
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.70
Return on Assets (ROA)-8.22
Return on Equity (ROE)-0.70
Identifiers and Descriptors
Central Index Key (CIK)25743
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)216.43
Scoring Models
Piotroski F Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Accumulated Depreciation And Depletion Per Share0.00
Inventory Per Share0.01
Minority Interest Per Share0.00
Liabilities Per Share0.06
Inventory Work In Progress Per Share0.00
Assets Current Per Share0.04
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Cash Per Share0.00
Debt Per Share0.00
Assets Other Non Current Per Share0.00
Accounts Receivable Per Share0.02
Retained Earnings Per Share-1.86
Inventory Finished Goods Per Share0.01
Liabilities Current Per Share0.06
Goodwill Per Share0.00
Property Plant And Equipment Net Per Share0.00
Intangibles Per Share0.01
Assets Per Share0.06
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Additional Paid In Capital Per Share2.62
Liabilities And Stock Equity Per Share0.82
Property Plant And Equipment Per Share0.00
Inventory Raw Materials Per Share0.00
Equity Per Share0.76
Cash And Equivalents Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00

Related News Stories

Your Daily Pharma Scoop: Intercept Updates On NASH Trial, GW Pharmaceuticals Provides Regulatory Update, Odonate Initiates Trial

2017-12-31 seekingalpha
Today we will discuss an update from Intercept Pharmaceuticals (ICPT) with regards to its REVERSE trial in NASH patients with compensated cirrhosis. (56-1)

TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise

2017-12-29 zacks
Shares of TherapeuticsMD, Inc. (TXMD - Free Report) were up 4.4% in after-market trading on Dec 28, following the submission of a new drug application (“NDA”) to the FDA for pipeline candidate, TX-001HR. (95-0)

10 Stocks to Buy for Surefire Gains in 2018 and Beyond

2017-12-27 investorplace
With everyone looking ahead now to 2018, investors are getting bombarded with ideas regarding the best stocks to buy. (328-4)

TherapeuticsMD: Class 2 Re-Submission Is Not The End Of The World

2017-12-25 seekingalpha
On December 19, 2017, TherapeuticsMD (NYSEMKT:TXMD) announced that the FDA has labeled the submission as Class 2 and will announce its decision on approval by May 29, 2018. The impact of Class 2 may not be as negative as what many have perceived. (2-1)

TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why

2017-12-20 zacks
TherapeuticsMD, Inc. (TXMD - Free Report) announced that the FDA has accepted the resubmission of the New Drug Application (“NDA”) for its dyspareunia candidate, TX-004HR. The FDA also set a PDUFA date of May 29, 2018. (77-2)

CUSIP: 88338N107